Table 22Characteristics of included placebo-controlled trials of serotonin and norepinephrine reuptake inhibitors

StudyArm Dose mg/Day (N)Duration (Weeks)Population Trauma TypeBaseline PTSD SeverityaMean Age (Y)% Female% Non-whiteRisk of Bias
Davidson et al., 200673Venlafaxine ER 37.5 to 300 mg (161)
Placebo (168)		24Male and female
Mixed		81 to 82.94154NRMedium
Davidson et al., 200669Total 538b Venlafaxine 37.5 to 375 mg (179)
Placebo (179)		12Male and female
Mixed		~82NRNRNRMedium
a

Data reported are mean CAPS or range of mean CAPS scores across groups unless another instrument is specified.

b

The Ns for each are the number analyzed and include a third study arm (sertraline 25 to 200 mg); the number randomized to each group was not reported (overall N was 538; 531 were included in the analysis).

CAPS = Clinician-Administered PTSD Scale; ER = extended release; F = female; mg = milligram; N = total number randomized/assigned to intervention and control groups; NR = not reported; PTSD = posttraumatic stress disorder; y = year.

From: Results

Cover of Psychological and Pharmacological Treatments for Adults With Posttraumatic Stress Disorder: A Systematic Review Update
Psychological and Pharmacological Treatments for Adults With Posttraumatic Stress Disorder: A Systematic Review Update [Internet].
Comparative Effectiveness Review, No. 207.
Forman-Hoffman V, Middleton JC, Feltner C, et al.
Copyright Notice

NCBI Bookshelf. A service of the National Library of Medicine, National Institutes of Health.